Compositions for preventing, reducing or treating keratinocyte-mediated inflammation

Abstract

The present invention relates to the field of epidermal repair. More particularly, the invention concerns the use of a molecule able to inhibit a heteromeric receptor comprising OSMRβ as a subunit, for the preparation of a composition for inhibiting the expression of inflammatory factors by the keratinocytes. In particular, the invention concerns the use of antagonists and/or expression inhibitors of OSM, IL-17, TNFα, IL-31, IFN-γ, and/or the OSMRβ subunit, for the preparation of cosmetic or dermatologic compositions, especially for treating inflammatory skin diseases. Methods for obtaining in vitro or animal models of skin inflammation diseases are also disclosed. These models can be used for screening molecules to find new drugs to prevent or treat psoriasis and other dermatitis.

1 . A method for improving epidermal repair in a patient in need thereof, comprising a step of administering a composition to said patient, wherein said composition comprises at least one molecule selected from the group consisting of antagonists and expression inhibitors of a cytokine selected amongst OSM, IL-17, TNFα, IL-31 and IFN-γ, and antagonists and expression inhibitors of the OSMRβ subunit. 
     
     
         2 . The method according to  claim 1 , wherein said composition prevents, reduces, or treats keratinocyte-mediated inflammation. 
     
     
         3 . The method according to  claim 1 , wherein said composition comprises an OSM antagonist and/or an IL-17 antagonist and/or a TNFα antagonist. 
     
     
         4 . The method according to  claim 1 , wherein said composition comprises an OSM expression inhibitor and/or an IL-17 expression inhibitor and/or a TNFα expression inhibitor and/or an OSMRβ expression inhibitor. 
     
     
         5 . The method according to  claim 4 , wherein said expression inhibitor is a siRNA. 
     
     
         6 . The method according to  claim 1  for preventing, alleviating or treating a skin inflammation disease selected from the group consisting of psoriasis, atopic dermatitis, bullous epidermolysis, bullous phemphigoid, lichen, acne, eczema, professional dermatitis, seborrheic dermatitis, keratosis, rosacea, erythema and ichtyosis. 
     
     
         7 . The method according to  claim 1 , wherein said composition inhibits keratinocyte migration. 
     
     
         8 . The method according to  claim 1 , wherein said composition prevents or reduces epidermal thickening. 
     
     
         9 . The method according to  claim 1 , wherein said composition slows down epidermal healing. 
     
     
         10 . The method according to  claim 1 , wherein said composition prevents and/or attenuates chaps on hands, lips, face or body. 
     
     
         11 . The method according to  claim 1 , wherein said composition prevents and/or attenuates stretch marks. 
     
     
         12 . The method according to  claim 1 , wherein said composition is used for improving the aspect and comfort of scars. 
     
     
         13 . The method according to  claim 1 , wherein said composition improves the aspect and comfort of epidermal wounds during their cicatrisation. 
     
     
         14 . The method according to  claim 1 , wherein the composition is a mixture containing at least two different molecules selected from the group consisting of antagonists and expression inhibitors of a cytokine selected amongst OSM, IL-17, TNFα, IL-31 and IFN-γ, and antagonists and expression inhibitors of the OSMRβ subunit. 
     
     
         15 . A method for preventing, reducing and/or treating keratinocyte-mediated inflammation in a patient in need thereof, comprising a step of administrating a composition to said patient, wherein said composition comprises an antagonist of OSM. 
     
     
         16 . The method according to  claim 15 , for preventing, reducing and/or treating psoriasis. 
     
     
         17 . The method according to  claim 15 , wherein said composition comprises an antagonist of OSM and an antagonist of IL-17. 
     
     
         18 . The method according to  claim 17 , for treating psoriasis.